Reig Jofre H1 2026 net income more than doubles to EUR 3.4 million; EBITDA rises 27% to EUR 17.9 million
Reuters2026/07/31 05:45- Laboratorio Reig Jofre posted H1 2026 net income of EUR 3.4 million, up 126%, as EBITDA climbed 27% to EUR 17.9 million.
- Revenue rose 1% to EUR 168.5 million, despite a temporary Forté Pharma supply-chain disruption in France and Belgium that was resolved in June.
- EBITDA margin improved to 10.7%, while net financial debt stood at EUR 117.7 million, implying a net debt-to-EBITDA ratio of 3.4x.
- Antibiotics sales increased 16% in Q2 versus Q2 2025 as the new Toledo injectable penicillin line began start-up; capacity is expected to lift output 50% over coming years.
- Forté Pharma sales fell 17% in H1, while Specialty Pharmacare sales rose 14% to EUR 67 million and Pharmaceutical Technologies slipped 2% to EUR 69 million.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Goldman Sachs remains bullish on the South Korean stock market: Driven by the AI memory boom, with a potential upside of up to 80%.
Goldman Sachs strategist Timothy Moe maintains his bullish target on the South Korean stock market, believing that investors are underestimating how long the benefits of artificial intelligence (AI) will last for the country's memory chip manufacturers.
Oranjebtc cancels 25 million treasury shares without capital reduction
The Last Time Treasury Yields Hit 6%, Bitcoin Didn't Exist — What Happens If They Get There Again?
Crypto prices
More
